Latest Headlines

Latest Headlines

Gilead looks overseas to guard Sovaldi profits from taxes

Tax inversion deals are not the only trick Big Pharma has up its sleeve to avoid steep U.S. taxes. Gilead Sciences is booking profits overseas in low-tax countries to take home more profits for its blockbuster hep C drug Sovaldi.

GSK annual report says China bribery case spawned surge in compliance 'contacts'

It turns out the GlaxoSmithKline whistleblowers who blew the top off the China corruption scandal had hundreds of copycats later on.

China's Tianyin Pharma faces NYSE de-listing on failure to file quarterly report

China's Tianyin Pharmaceutical may be in danger of being de-listed from the New York Stock Exchange for failing to file its latest quarterly report on time.

South Korea pregnancy test kit and contraceptive sales firm up after adultery law struck down

Several South Korea drug and medical-device makers can expect to be the big winners from a Constitutional Court ruling striking down the nation's law making adultery a federal crime. The law was passed in 1953 to protect women.

Japan's Daiichi Sankyo revamps operations, management, ahead of olmesartan expiry

Daiichi Sankyo has revamped management roles and will cut reporting lines on April 1, ahead of the looming loss of its patent protection of flagship hypertension drug olmesartan (Benicar) in key markets this year to shore up its group structure.

GSK CEO Witty's pay whacked as U.K.'s largest drugmaker struggles to right itself

2014 was a tough year for GlaxoSmithKline. Its revenues and profits were off significantly. Its operating profit was off nearly 50% in pounds--and, as it turns out, so was CEO Andrew Witty's pay. In fact he took a 46% whack to his compensation.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets (Part 2)

Here is part two of comments from C-suite execs on emerging markets and Asia in the latest quarterly conference calls.

Google Ventures funds tablet for the elderly

Entrepreneur Keith Kocho is designing a smart tablet specifically for the elderly. He's been given $1 million from Google Ventures and Atlas Venture to work on the project.

DexCom profitable for the first time, completes FDA submission for smartphone glucose monitor

Continuous glucose monitor company DexCom turned a profit for the first time during the fourth quarter of last year. It also said it completed its FDA submission for its first direct-access smartphone CGM, the G5, which transmits data directly to a smartphone and from the phone to a secure system.

Bayer counts on consumer health, pharma growth to power 2015

Bayer's new pharma launches may be soaring, but that wasn't enough to help the German drugmaker meet analysts' profit estimates for Q4. For 2015, the company expects bigger things--but as it moves forward with plans to bid farewell to its plastics unit and competition ramps up for its best-sellers, its consumer health division will need to start pulling its weight.